PL3086793T3 - Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu zaburzenia czynności nerek - Google Patents

Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu zaburzenia czynności nerek

Info

Publication number
PL3086793T3
PL3086793T3 PL14874617.5T PL14874617T PL3086793T3 PL 3086793 T3 PL3086793 T3 PL 3086793T3 PL 14874617 T PL14874617 T PL 14874617T PL 3086793 T3 PL3086793 T3 PL 3086793T3
Authority
PL
Poland
Prior art keywords
ocs
treatment
kidney dysfunction
oxygenated cholesterol
cholesterol sulfates
Prior art date
Application number
PL14874617.5T
Other languages
English (en)
Inventor
Shunlin Ren
Felix Theeuwes
James E. Brown
Weiqi Lin
Original Assignee
Virginia Commonwealth University
The United States Government As Represented By The Department Of Veterans Affairs
Durect Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University, The United States Government As Represented By The Department Of Veterans Affairs, Durect Corporation filed Critical Virginia Commonwealth University
Publication of PL3086793T3 publication Critical patent/PL3086793T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Physiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Biophysics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL14874617.5T 2013-12-24 2014-12-23 Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu zaburzenia czynności nerek PL3086793T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361920617P 2013-12-24 2013-12-24
PCT/US2014/072128 WO2015100312A1 (en) 2013-12-24 2014-12-23 Uses of oxygenated cholesterol sulfates (ocs)

Publications (1)

Publication Number Publication Date
PL3086793T3 true PL3086793T3 (pl) 2023-01-30

Family

ID=53479646

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14874617.5T PL3086793T3 (pl) 2013-12-24 2014-12-23 Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu zaburzenia czynności nerek
PL19214560T PL3639828T3 (pl) 2013-12-24 2014-12-23 Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL19214560T PL3639828T3 (pl) 2013-12-24 2014-12-23 Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby

Country Status (25)

Country Link
US (4) US10272097B2 (pl)
EP (3) EP3086793B1 (pl)
JP (4) JP7009059B2 (pl)
KR (3) KR102530119B1 (pl)
CN (2) CN113599388A (pl)
AU (3) AU2014369916A1 (pl)
BR (1) BR112016014611A8 (pl)
CA (2) CA2932300C (pl)
CY (2) CY1125028T1 (pl)
DK (2) DK3639828T3 (pl)
EA (2) EA201990684A1 (pl)
ES (2) ES2906865T3 (pl)
HR (2) HRP20220978T1 (pl)
HU (2) HUE059914T2 (pl)
IL (3) IL282010B (pl)
LT (2) LT3639828T (pl)
MX (4) MX2021011641A (pl)
PL (2) PL3086793T3 (pl)
PT (2) PT3086793T (pl)
RS (2) RS63002B1 (pl)
SI (2) SI3639828T1 (pl)
SM (2) SMT202200314T1 (pl)
TW (4) TWI816417B (pl)
WO (1) WO2015100312A1 (pl)
ZA (1) ZA201603580B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
EP3086793B1 (en) * 2013-12-24 2022-05-11 Virginia Commonwealth University Use of oxygenated cholesterol sulfates (ocs) for the treatment of kidney dysfunction
WO2017086436A1 (ja) * 2015-11-20 2017-05-26 国立大学法人九州大学 免疫制御剤
WO2017189561A1 (en) * 2016-04-25 2017-11-02 Mennerick Steve 25-hydroxycholesterol and methods of use thereof
KR20230124756A (ko) * 2016-08-02 2023-08-25 버지니아 커먼웰스 유니버시티 염증성 피부 질환 및 피부 병변을 치료하기 위한 산소첨가된콜레스테롤 술페이트 (ocs) 의 용도
MX391441B (es) * 2016-08-02 2025-03-21 Durect Corp Composiciones que comprenden sulfato de colesterol oxigenado y por lo menos uno de poli-alquilen-glicol, carboxi-metil-celulosa y polioxilglicerido.
KR102465046B1 (ko) 2016-08-02 2022-11-10 버지니아 커먼웰스 유니버시티 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물
KR20220075329A (ko) * 2019-09-30 2022-06-08 듀렉트 코퍼레이션 알콜성 간염의 치료
CA3165765A1 (en) * 2019-12-27 2021-07-01 Durect Corporation Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same
AU2021221109A1 (en) * 2020-02-11 2022-08-25 Durect Corporation Treatment of infectious diseases
CN112394102B (zh) * 2020-11-05 2023-05-26 上海交通大学医学院附属瑞金医院 一种检测垂体功能减退症的标志物及其应用
JP7593781B2 (ja) * 2020-11-09 2024-12-03 株式会社三共 遊技機
JP7593782B2 (ja) * 2020-11-09 2024-12-03 株式会社三共 遊技機
JP7593783B2 (ja) * 2020-11-09 2024-12-03 株式会社三共 遊技機
JP7593784B2 (ja) * 2020-11-09 2024-12-03 株式会社三共 遊技機
JP7640986B2 (ja) * 2020-12-03 2025-03-06 学校法人慈恵大学 挫滅症候群の診断補助方法およびそれに使用されるプログラム
CN114306350B (zh) * 2022-01-13 2023-01-24 四川大学华西医院 胆固醇硫酸盐在制备预防脓毒症的药物中的用途
CN114646702B (zh) * 2022-03-03 2023-01-06 四川大学华西医院 胆固醇硫酸酯检测试剂在制备脓毒症辅助诊断、治疗效果监测和预后评估试剂盒中的用途
WO2024097247A1 (en) * 2022-10-31 2024-05-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists
WO2025101669A1 (en) 2023-11-07 2025-05-15 Durect Corporation Treatment of alcohol-associated hepatitis

Family Cites Families (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794362A (fr) 1972-01-22 1973-07-23 Merck Patent Gmbh Sulfates hydrosolubles de sterine
US3928397A (en) 1973-03-02 1975-12-23 Eisai Co Ltd New 5-cholestene derivatives and preparation thereof
US3822254A (en) 1973-05-21 1974-07-02 Hoffmann La Roche Synthesis of 25-hydroxycholesterol
US4264512A (en) 1975-09-29 1981-04-28 The Regents Of The University Of California 3-Deoxy-1α-hydroxy- and 3-deoxy-1α,25-dihydroxycholecalciferol and processes for the preparation thereof
US4049803A (en) 1976-04-26 1977-09-20 Bristol-Myers Company Augmentation of blood levels of aspirin
CA1083044A (en) 1976-05-04 1980-08-05 Stewart Wong Antiarthritic potentiation
US4202891A (en) 1977-05-16 1980-05-13 Kandutsch Andrew A 15-Oxygenated sterol compounds and the use of such compounds to inhibit the biosynthesis of sterols
GB1595020A (en) 1977-06-24 1981-08-05 Chugai Pharmaceutical Co Ltd 3a-hydroxy steroid derivatives of the cholestane series
US4234601A (en) 1978-12-18 1980-11-18 Mcneilab, Inc. Analgesic potentiation
US4233317A (en) 1978-12-18 1980-11-11 Mcneilab, Inc. Analgesic potentiation
US4233315A (en) 1978-12-18 1980-11-11 Mcneilab, Inc. Analgesic potentiation
US4207340A (en) 1978-12-18 1980-06-10 Mcneilab, Inc. Analgesic potentiation
US4242353A (en) 1978-12-18 1980-12-30 Mcneilab, Inc. Analgesic potentiation
US4233314A (en) 1978-12-18 1980-11-11 Mcneilab, Inc. Analgesic potentiation
US4233313A (en) 1978-12-18 1980-11-11 Mcneilab, Inc. Analgesic potentiation
US4233316A (en) 1978-12-18 1980-11-11 Mcneilab, Inc. Analgesic potentiation
US4237140A (en) 1979-05-18 1980-12-02 E. I. Du Pont De Nemours And Company Analgesic mixture of nalbuphine and acetaminophen
US4260629A (en) 1979-10-25 1981-04-07 E. I. Du Pont De Nemours And Company Treating pain with acetaminophen and 1,4-dimethyl-5-p-chlorobenzoyl-pyrrole-2-acetic acid
US4314989A (en) 1980-05-07 1982-02-09 Rosen Gerald M Methionine sulfoxide amflioration of acetaminophen toxicity
US4307073A (en) 1980-08-08 1981-12-22 The Research Foundation Of State University Of New York Method and composition for reducing the toxicity of acetaminophen
US4401665A (en) 1981-04-14 1983-08-30 Bristol-Myers Company Sleep-aid composition containing an analgesic and diphenhydramine dihydrogencitrate, and method of use
US4460368A (en) 1981-10-29 1984-07-17 Almedco, Inc. Trans-dermal medication system
US4427668A (en) 1982-04-01 1984-01-24 New York University 26-Hydroxycholesterol and derivatives and analogs thereof in regulation of cholesterol accumulation in body tissue
US4794112A (en) 1982-12-09 1988-12-27 Cooper Stephen A Acetaminophen/hydroxyzine analgesic combinations
US4478822A (en) 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4476115A (en) 1983-07-05 1984-10-09 Reed Raymond E Analgesic composition and method of treating subdermal pain
GB8325627D0 (en) 1983-09-24 1983-10-26 Scras Therapeutic compositions
US4466960A (en) 1983-10-18 1984-08-21 Thompson Medical Co., Inc. Analgesic-diuretic compositions
US4681897A (en) 1984-01-16 1987-07-21 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US6217911B1 (en) 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4730007A (en) 1985-09-04 1988-03-08 Seymour Ehrenpreis Novel analgesic compositions
US4743597A (en) 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
US4971960A (en) 1986-03-11 1990-11-20 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acids
US5238686A (en) 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US4829064A (en) 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US5011688A (en) 1989-02-02 1991-04-30 Calam Henry D Liquid composition for the relief of premenstrual and menstrual discomforts
US5891801A (en) 1987-07-17 1999-04-06 Calam And Associates, Inc. Palatable liquid-admininstered oral medicaments for relief of discomfort and flavoring combinations therefor
US5468482A (en) 1987-07-17 1995-11-21 Calam & Associates, Inc. Palatable orally administered liquid medicaments for relief of discomfort and flavoring combinations therefor
US4822781A (en) 1987-10-08 1989-04-18 American Home Products Substituted-8-alkenyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acids
US6127352A (en) 1988-02-01 2000-10-03 Uribe; Jose R. Pharmaceutical compositions with analgesics containing codeine
US4971785A (en) 1988-03-14 1990-11-20 Spectrum Consumer Products Co., Inc. Non-alcoholic delivery system for orally ingestible active ingredients
US4990535A (en) 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5036097A (en) 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
US5023085A (en) 1989-11-29 1991-06-11 Pfizer Inc. Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
JPH0714872B2 (ja) 1990-02-06 1995-02-22 昭和薬品化工株式会社 シロップ剤組成物
CA2020018A1 (en) 1990-06-27 1991-12-28 Don L. Simmons Method and composition for treating the migraine complex
US5296241A (en) 1991-04-03 1994-03-22 Brimberg Barnett J Therapeutic composition and method of using same for treatment of hangover
ES2120451T7 (es) 1991-09-06 2009-11-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Composicion que comprende un compuesto de tramadol y acetaminofeno, y su uso.
US5409709A (en) 1991-11-29 1995-04-25 Lion Corporation Antipyretic analgesic preparation containing ibuprofen
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5322689A (en) 1992-03-10 1994-06-21 The Procter & Gamble Company Topical aromatic releasing compositions
US5510340A (en) 1992-06-12 1996-04-23 Sri International Antihypercholesterolemic compounds and related pharmaceutical compositions and methods of use
US5306711A (en) 1992-06-24 1994-04-26 Georgetown University Organ preservative solution
US5371077A (en) 1992-08-03 1994-12-06 William Marsh Rice University Side chain derivatized 15-oxygenated sterols, methods of using them and a process for preparing them
US6303632B1 (en) 1992-09-03 2001-10-16 Sepracor Inc. Compositions for treating allergic and other disorders using norastemizole in combination with other active ingredients
US5474757A (en) 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
US5260340A (en) 1992-11-19 1993-11-09 Baranowitz Steven A Prevention and amelioration of acetaminophen toxicity with beta-carotene
US5724957A (en) 1993-01-29 1998-03-10 Aradigm Corporation Intrapulmonary delivery of narcotics
US5599659A (en) * 1993-03-11 1997-02-04 Breonics, Inc. Preservation solution for ex vivo, warm preservation of tissues, explants,organs and vascular endothelial cells comprising retinal-derived fibroblast growth factor, cyclodextrin and chondroitin sulfate
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2161217A1 (en) 1993-04-30 1994-11-10 Carmelita Macklin Russell Coated pharmaceutical compositions
US5466865A (en) 1993-07-02 1995-11-14 Ibah, Inc. Neomorphic ibuprofen and methods of using same
US5587368A (en) 1993-11-30 1996-12-24 New York University Administration of a 27-hydroxycholesterol or related compound or sterol-27-hydroxylase stimulant to prevent restenosis following vascular endothelial injury
GB9403857D0 (en) 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US5458879A (en) 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
US6077533A (en) 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US6482831B1 (en) 1994-06-16 2002-11-19 Entropin, Inc. Covalently coupled benzoylecgonine, egconine and ecgonidine derivatives
US5612061A (en) 1994-10-14 1997-03-18 Rabkin; Simon W. Composition and method for the treatment of premenstrual syndrome
JP3828603B2 (ja) * 1994-12-26 2006-10-04 株式会社日清製粉グループ本社 ピロリジノン誘導体を含有する医薬組成物
US5538959A (en) 1995-01-26 1996-07-23 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US6645953B2 (en) 1995-06-23 2003-11-11 Novo Nordisk A/S Meiosis regulating compounds
CA2224866A1 (en) 1995-06-23 1997-01-09 Novo Nordisk A/S Meiosis regulating compounds
US5654334A (en) 1995-06-23 1997-08-05 Oklahoma Medical Research Foundation Analgesic use of N-L-α-aspartyl-L-phenylalanine 1-methyl ester
US5840731A (en) 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
JPH0971581A (ja) * 1995-09-08 1997-03-18 Nisshin Flour Milling Co Ltd ラクタム誘導体
US5897880A (en) 1995-09-29 1999-04-27 Lam Pharmaceuticals, Llc. Topical drug preparations
CN1102852C (zh) 1995-11-13 2003-03-12 皮特迈国际有限公司 含一氧化二氮的止痛药、消炎药和解热药的给药介质及含有这样的介质和药物的药物组合物
US6391337B2 (en) 1995-11-15 2002-05-21 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
US5733578A (en) 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
US6852336B2 (en) 1995-11-15 2005-02-08 J. Rettenmaier & Soehne Gmbh + Co. Kg Directly compressible high load acetaminophen formulations
US6214386B1 (en) 1995-11-22 2001-04-10 Recordati, S.A. Prompt-release oral pharmaceutical compositions for extemporaneous suspensions
CA2239301A1 (en) 1995-12-06 1997-06-12 Charles Howard Mitch Composition for treating pain
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
CN1146421C (zh) 1996-03-25 2004-04-21 伊莱利利公司 治疗疼痛的组合物以及药物在制备所述组合物中的应用
EP0906104A4 (en) 1996-03-25 2003-12-10 Lilly Co Eli PAIN TREATMENT PROCESS
US5837729A (en) 1996-04-26 1998-11-17 Metatron, Inc. Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof
US5739139A (en) 1996-06-20 1998-04-14 Mcneil-Ppc, Inc. Acetaminophen and dimenhydrinate analgesics
JPH1072421A (ja) * 1996-07-02 1998-03-17 Nisshin Flour Milling Co Ltd イミド誘導体
US5914129A (en) 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
FR2751875B1 (fr) 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
US5872145A (en) 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
WO1998007447A1 (en) 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
US5919826A (en) 1996-10-24 1999-07-06 Algos Pharmaceutical Corporation Method of alleviating pain
US6077539A (en) 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
US5776462A (en) 1996-12-10 1998-07-07 Sage R&D, A Partnership Pogostemon cablin extract for inhibiting H. influenzae adhesion and treating otitis media or sore throat
CA2650204A1 (en) 1996-12-31 1998-07-09 Harry B. Demopoulos Pharmaceutical preparations of glutathione and methods of administration thereof
US6048540A (en) 1997-01-29 2000-04-11 Chong Kun Dang Corp. Acetamenophen composition with reduced liver toxicity
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US5891477A (en) 1997-03-28 1999-04-06 Biohybrid Technologies, Inc. Non-steroidal anti-inflammatory agents inhibition of fibrotic response to an implanted device
US5972916A (en) 1997-07-14 1999-10-26 Bristol-Myers Squibb Company Compositions containing the nonprescription combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine
US6077530A (en) 1997-07-28 2000-06-20 Weinstein; Robert Analgesic dosage units for coordinated administration
GB2328443B (en) 1997-08-21 2001-09-05 Reckitt & Colmann Prod Ltd In situ formation of pharmaceutically acceptable polymeric material
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
US8409846B2 (en) 1997-09-23 2013-04-02 The United States Of America As Represented By The Department Of Veteran Affairs Compositions, methods and devices for maintaining an organ
US5965167A (en) 1997-10-07 1999-10-12 Sanghvi; Pradeepkumar P. Dosage units
US6162647A (en) 1997-10-14 2000-12-19 Stephens; James Matthew Method for removing interfering substances from a urine sample using a chemical oxidant
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
ES2412409T3 (es) 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
US6413512B1 (en) 1998-02-13 2002-07-02 National Enzyme Company Composition and method for treating disease by increasing activated α2 macroglobulin in the blood and extravascular tissue
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6242493B1 (en) 1998-03-13 2001-06-05 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
US6054451A (en) 1998-04-21 2000-04-25 Algos Pharmaceutical Corporation Analgesic composition and method for alleviating pain
CN1326461A (zh) 1998-05-13 2001-12-12 诺沃挪第克公司 减数分裂调控化合物
KR20010043558A (ko) 1998-05-13 2001-05-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 감수분열 조절 화합물
US6254891B1 (en) 1998-09-03 2001-07-03 Ascent Pediatrics, Inc. Extended release acetaminophen
US6126967A (en) 1998-09-03 2000-10-03 Ascent Pediatrics Extended release acetaminophen particles
US6485747B1 (en) 1998-10-30 2002-11-26 Monsanto Company Coated active tablet(s)
ES2194536T3 (es) 1998-11-13 2003-11-16 Lilly Co Eli Combinacion de duloxetina con farmacos antiinflamatorios no esteroideos.
US6627234B1 (en) 1998-12-15 2003-09-30 Wm. Wrigley Jr. Company Method of producing active agent coated chewing gum products
US6586023B1 (en) 1998-12-15 2003-07-01 Wm. Wrigley Jr. Company Process for controlling release of active agents from a chewing gum coating and product thereof
US6139861A (en) 1999-01-14 2000-10-31 Friedman; Mark Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383527B1 (en) 1999-03-04 2002-05-07 Nps Pharmaceuticals, Inc. Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID
US6365338B1 (en) 1999-04-27 2002-04-02 David A. Bull Organ preservative solution containing trehalose, anti-oxidant, cations and an energy source
MXPA01011070A (es) 1999-04-30 2003-06-30 Arch Dev Corp Derivados de esteroides.
US20060025393A1 (en) 1999-04-30 2006-02-02 Shutsung Liao Steroid derivatives
US6383515B2 (en) 1999-05-28 2002-05-07 Sawyer Maryjean Solvent system for enhancing solubility
US6566361B2 (en) 1999-06-30 2003-05-20 Laboratories, Upsa Azapirone pain treatment
FR2795645B1 (fr) 1999-06-30 2001-09-21 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
MXPA01013109A (es) 1999-07-14 2002-06-04 Coca Cola Co Compartimiento promocional ventilado.
US6642243B1 (en) 1999-07-22 2003-11-04 Ashkan Imanzahrai Migraine medicine and method for treating same
JP2003520780A (ja) 1999-09-01 2003-07-08 ユニバーシティ オブ ブリティッシュ コロンビア Ｈｄｌコレステロールとトリグリセリド水準を調節する組成物と方法
US6544548B1 (en) 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
DE60008399T2 (de) 1999-09-14 2004-12-09 Merck Frosst Canada & Co, Kirkland Carbonsäuren und acylsulfonamide, solche verbindungen enthaltende zubereitungen und behandlungsmethoden
DE60024648T2 (de) 1999-09-14 2006-08-10 Merck Frosst Canada & Co, Kirkland Carbonsäuren und acylsulfonamide, diese verbindungen enthaltende zubereitungen und behandlungsmethoden
US6524623B1 (en) 1999-11-12 2003-02-25 Milton Hodosh Therapeutic compositions and methods of use thereof
KR100416242B1 (ko) 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
US6492334B1 (en) 1999-12-30 2002-12-10 Robert James Generale Tri-compound analgesic for treating inflammation and pain
JP4018312B2 (ja) 2000-02-21 2007-12-05 株式会社ルネサステクノロジ 無線通信装置
US6841544B2 (en) 2000-02-23 2005-01-11 Bioselect Innovations, Inc. Composition and method for treating the effects of diseases and maladies
US6787164B2 (en) 2000-02-23 2004-09-07 Bioselect Innovations, Inc. Composition and method for treating the effects of diseases and maladies
US7611830B2 (en) 2000-04-10 2009-11-03 The United States Of America As Represented By The Department Of Veteran's Affairs Device to lavage a blood vessel
US6686390B2 (en) 2000-05-22 2004-02-03 Dr. Reddy's Laboratories Limited Compounds having antiinflamatory activity: process for their preparation and pharmaceutical compositions containing them
US6306842B1 (en) 2000-06-02 2001-10-23 Medinox, Inc. Protected forms of a combination of pharmacologically active agents and uses therefor
US6833362B2 (en) 2000-06-12 2004-12-21 Ward Beryl Bowen, Jr. Method and composition for the accelerated in vivo removal of ethanol
US6355666B1 (en) 2000-06-23 2002-03-12 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US6740333B2 (en) 2000-07-07 2004-05-25 Anestic Aps Suppository and composition comprising at least one polyethylene glycol
US6696238B2 (en) 2000-07-28 2004-02-24 Christopher J. Murphy Transplant media
US6225295B1 (en) 2000-09-27 2001-05-01 Frederick H. Hausheer Method of treating acetaminophen overdose
US6924273B2 (en) 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
US6391886B1 (en) 2000-12-04 2002-05-21 The Procter & Gamble Company Oral compositions having improved consumer aesthetics
US6440983B1 (en) 2000-12-21 2002-08-27 Mary Theresa Frank-Kollman Compositions and methods for relieving headache symptoms in aspirin-sensitive headache sufferers
JP2005508281A (ja) 2001-02-08 2005-03-31 ザ ユニバーシティー オブ シカゴ ステロイド誘導体
US20020164310A1 (en) 2001-03-02 2002-11-07 Mgvs Ltd. Nucleic acid constructs, cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension
US6566401B2 (en) 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US6593331B2 (en) 2001-04-17 2003-07-15 Laboratories Upsa Method for treatment of pain
US6622856B2 (en) 2001-04-25 2003-09-23 Johnson & Johnson Consumer Companies, Inc. Relief kit
ATE375994T1 (de) 2001-05-03 2007-11-15 Univ Chicago Leber x rezeptoragonisten
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
MXPA03011017A (es) 2001-06-01 2005-04-29 Pozen Inc Composiciones farmaceuticas para la entrega coordinada de nsaids.
US6475526B1 (en) 2001-06-05 2002-11-05 Jeffrey B. Smith Zinc containing compositions for anti-viral use
US6602518B2 (en) 2001-06-28 2003-08-05 Wm. Wrigley Jr. Company Chewable product including active ingredient
US6613346B2 (en) 2001-06-28 2003-09-02 Wm. Wrigley, Jr. Company Chewable product including active ingredient
TW200300078A (en) 2001-11-08 2003-05-16 Univ Chicago Method of treating disorder related to high cholesterol concentration
US6569439B1 (en) 2001-11-13 2003-05-27 Noville Inc. Process for making personal care compositions comprising titanium dioxide and personal care compositions made by the process
US6509380B1 (en) 2001-12-14 2003-01-21 Marshall University Research Corporation Method of treating iron overload with acetaminophen
US6828328B1 (en) 2002-03-01 2004-12-07 Ucb S.A. Analgesic combination of muscarinic agonists
JP4570877B2 (ja) 2002-03-28 2010-10-27 明治製菓株式会社 臓器保存用組成物および臓器の保存方法
DE10222561B4 (de) 2002-05-17 2009-12-10 Dr. Franz Köhler Chemie GmbH Protektive Lösung zur Verhinderung von Ischämieschäden
UA79984C2 (en) 2002-08-20 2007-08-10 Bristol Myers Squibb Co Preparation on the basis of aripiprazole complex and use thereof
US6702850B1 (en) 2002-09-30 2004-03-09 Mediplex Corporation Korea Multi-coated drug-eluting stent for antithrombosis and antirestenosis
EP1475434A1 (en) 2003-05-09 2004-11-10 Oncoscience AG Method for storing tumor cells
CN1976906B (zh) 2004-06-30 2010-09-01 詹森药业有限公司 用作parp抑制剂的取代2-烷基喹唑啉酮衍生物
US20060047022A1 (en) 2004-08-30 2006-03-02 Craig Daniel H Thermoplastic compositions including inorganic particulates
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
DE102006021181B3 (de) 2006-05-06 2007-05-03 Laux, Thomas, Dr. Zahnprothesen-Trägerimplantat
CN101134100B (zh) * 2006-09-01 2010-11-10 复旦大学 类固醇激素合成急性调节蛋白在制备防治脂肪肝药物中的用途
JP5120998B2 (ja) 2006-09-06 2013-01-16 国立大学法人 東京医科歯科大学 組織、細胞又は臓器の保存液
GB0625965D0 (en) 2006-12-23 2007-02-07 Renovo Ltd Medicaments for wound healing
US8831674B2 (en) 2007-09-27 2014-09-09 Multi-Tech Systems, Inc. Message server
JPWO2009084743A1 (ja) 2007-12-28 2011-05-19 ミズ株式会社 治療または予防のための外用剤
WO2009088192A2 (ko) * 2008-01-04 2009-07-16 Lg Life Sciences Ltd. 세포, 조직 및 장기 보존 효과를 갖는 인돌 및 인다졸 유도체
US8329450B2 (en) 2008-08-01 2012-12-11 Biomedinnovations, Llc Methods and apparatus for organ support
WO2011035005A2 (en) 2009-09-16 2011-03-24 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for reducing the risk of agent-induced liver toxicity
WO2011077245A2 (en) 2009-12-23 2011-06-30 Fondazione Centro San Raffaele Del Monte Tabor Compositions
EP2902019B1 (en) 2010-08-04 2017-10-04 Pierrel Pharma S.R.L. Compositions comprising inclusion complexes of cyclodextrins with spermidine for use in oral care
KR101739816B1 (ko) 2010-12-01 2017-05-25 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 주사용 액제 조성물 또는 주사용 건조 분말
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
US9585380B2 (en) 2011-09-02 2017-03-07 Temple University—Of the Commonwealth System of Higher Education SSAT mRNA translation repression and activation
AU2012304412A1 (en) 2011-09-08 2014-03-27 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US8665030B2 (en) 2011-12-14 2014-03-04 Taiwan Semiconductor Manufacturing Company, Ltd. Voltage-controlled oscillator
EA026683B1 (ru) 2012-04-12 2017-05-31 Вирджиния Коммонвелт Юниверсити МЕТАБОЛИТ ХОЛЕСТЕРИНА ДИСУЛЬФАТ 5-ХОЛЕСТЕН-3β,25-ДИОЛА (25HCDS) ДЛЯ ТЕРАПИИ НАРУШЕНИЙ ОБМЕНА ВЕЩЕСТВ, ГИПЕРЛИПИДЕМИИ, ДИАБЕТА, ЖИРОВЫХ БОЛЕЗНЕЙ ПЕЧЕНИ И АТЕРОСКЛЕРОЗА
KR20150036578A (ko) 2012-07-17 2015-04-07 더 리젠츠 오브 더 유니버시티 오브 미시간 백내장의 치료를 위한 알파-크리스탈린 응집의 억제제
EP2842547A1 (en) 2013-08-27 2015-03-04 Freund Pharmatec Ltd. Improved fenofibrate compositions
EP3086793B1 (en) 2013-12-24 2022-05-11 Virginia Commonwealth University Use of oxygenated cholesterol sulfates (ocs) for the treatment of kidney dysfunction
CA2963938C (en) 2014-10-07 2023-10-24 Sage Therapeutics, Inc. Neuroactive compounds and methods of use thereof
WO2016058000A1 (en) 2014-10-10 2016-04-14 Virginia Commonwealth University Oxygenated cholesterol sulfates for therapy of disorders caused by at least one of attenuated leptin activity and a lipid storage disorder
US10398709B2 (en) 2015-07-27 2019-09-03 Catacore, Inc. Compositions for the treatment of cataracts
KR20230124756A (ko) 2016-08-02 2023-08-25 버지니아 커먼웰스 유니버시티 염증성 피부 질환 및 피부 병변을 치료하기 위한 산소첨가된콜레스테롤 술페이트 (ocs) 의 용도
MX391441B (es) 2016-08-02 2025-03-21 Durect Corp Composiciones que comprenden sulfato de colesterol oxigenado y por lo menos uno de poli-alquilen-glicol, carboxi-metil-celulosa y polioxilglicerido.
KR102465046B1 (ko) 2016-08-02 2022-11-10 버지니아 커먼웰스 유니버시티 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물

Also Published As

Publication number Publication date
EP3086793A4 (en) 2018-01-10
EP4082550A1 (en) 2022-11-02
JP7364759B2 (ja) 2023-10-18
BR112016014611A8 (pt) 2023-05-09
EP3086793B1 (en) 2022-05-11
JP2020186241A (ja) 2020-11-19
MX2021011641A (es) 2023-03-10
HUE059914T2 (hu) 2023-01-28
IL246339A0 (en) 2016-08-31
IL294448A (en) 2022-09-01
EA201691305A1 (ru) 2016-10-31
HRP20220112T1 (hr) 2022-04-15
RS63474B1 (sr) 2022-08-31
EA032777B1 (ru) 2019-07-31
JP2023002544A (ja) 2023-01-10
US10786517B2 (en) 2020-09-29
CA2932300C (en) 2023-07-18
SI3086793T1 (sl) 2022-10-28
US20210046091A1 (en) 2021-02-18
KR102655918B1 (ko) 2024-04-09
CN113599388A (zh) 2021-11-05
AU2020202891A1 (en) 2020-05-21
BR122022016077A2 (pl) 2017-08-08
KR102530119B1 (ko) 2023-05-08
CN105899213A (zh) 2016-08-24
CA2932300A1 (en) 2015-07-02
KR20230065387A (ko) 2023-05-11
TW201609110A (zh) 2016-03-16
IL282010B (en) 2022-07-01
ZA201603580B (en) 2017-09-27
BR122022016077A8 (pt) 2023-05-09
JP7289030B2 (ja) 2023-06-09
LT3639828T (lt) 2022-03-25
EP3639828A1 (en) 2020-04-22
SMT202200094T1 (it) 2022-05-12
MX377151B (es) 2025-03-07
US11612609B2 (en) 2023-03-28
LT3086793T (lt) 2022-08-25
AU2022204450A1 (en) 2022-07-14
PL3639828T3 (pl) 2022-05-02
AU2014369916A1 (en) 2016-06-16
US20190350945A1 (en) 2019-11-21
US20170014429A1 (en) 2017-01-19
KR20240051283A (ko) 2024-04-19
SI3639828T1 (sl) 2022-04-29
HRP20220978T1 (hr) 2022-11-11
EP3639828B8 (en) 2022-01-05
TW202313060A (zh) 2023-04-01
EP3086793A1 (en) 2016-11-02
WO2015100312A1 (en) 2015-07-02
CA3195252A1 (en) 2015-07-02
IL282010A (en) 2021-05-31
HUE057649T2 (hu) 2022-05-28
EP3639828B1 (en) 2021-12-01
BR112016014611A2 (pt) 2017-08-08
CN105899213B (zh) 2021-03-16
RS63002B1 (sr) 2022-03-31
AU2022204450B2 (en) 2024-08-29
EA201990684A1 (ru) 2020-12-30
CY1125028T1 (el) 2023-06-09
TWI816417B (zh) 2023-09-21
US20230310458A1 (en) 2023-10-05
MX389828B (es) 2025-03-20
KR20160102301A (ko) 2016-08-29
MX2023002679A (es) 2023-04-03
MX2016008459A (es) 2016-10-14
JP2024009887A (ja) 2024-01-23
JP2017505761A (ja) 2017-02-23
DK3086793T3 (da) 2022-08-01
JP7009059B2 (ja) 2022-02-10
PT3639828T (pt) 2022-02-04
ES2906865T3 (es) 2022-04-20
SMT202200314T1 (it) 2022-09-14
AU2020202891B2 (en) 2022-03-24
ES2922501T3 (es) 2022-09-15
MX2019003547A (es) 2019-06-17
TW202137988A (zh) 2021-10-16
TWI734665B (zh) 2021-08-01
PT3086793T (pt) 2022-07-20
TW202348234A (zh) 2023-12-16
US10272097B2 (en) 2019-04-30
TWI782421B (zh) 2022-11-01
IL246339B (en) 2021-04-29
CY1125475T1 (el) 2025-05-09
DK3639828T3 (da) 2022-02-14

Similar Documents

Publication Publication Date Title
SMT202200314T1 (it) Uso di solfati di colesterolo ossigenati (ocs) per il trattamento di disfunzione epatica
IL268094B (en) History of heterocyclic compounds for use in the treatment of lung cancer
PL3811943T3 (pl) Związek do stosowania w leczeniu zaburzeń oczu
EP3030302A4 (en) Improvements to flow therapy
IL240765A0 (en) Macrocyclic daza-furanones for the treatment of viral infections
SG10201500791RA (en) Liquid filtering structure
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
PL3511004T3 (pl) Preparaty skojarzone do leczenia raka
PL2807170T3 (pl) Limonoidy fragmaliny do leczenia dysfunkcji seksualnych
PL3062790T3 (pl) Połączenia farmaceutyczne do leczenia raka
EP3225296A4 (en) Hybrid liquid filter structure
EP2991650A4 (en) Methods for the treatment of cancer
GB201317960D0 (en) Water treatment
GB201302839D0 (en) Water Treatment
ZA201604412B (en) Water treatment
EP3016948B8 (en) 2-acylaminothiazoles for the treatment of cancer
GB201416965D0 (en) Water treatment
AU2013905040A0 (en) Water treatment structure
HK1172889B (en) Water treatment
HK1172889A (en) Water treatment
HK1172890A (en) Water treatment
HK1172887B (en) Water treatment
HK1172887A (en) Water treatment
HK1172886B (en) Water treatment
HK1172886A (en) Water treatment